Metronidazole: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Metronidazole appears in the FDA drug-label database. Marketed as Metronidazole.
- Drug class
- Nitroimidazole Antimicrobial (FDA established pharmacologic class)
- Boxed warning
- The FDA label for Metronidazole carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become re…
FDA recalls / enforcement
| Reason (FDA) | Classification | Status | Initiated |
|---|---|---|---|
| Presence of Particulate Matter: identified as a cloth fiber. — Baxter Healthcare Corp. | Class I (FDA: reasonable probability of serious harm or death) | Terminated | 2016-01-21 |
| Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port. — Baxter Healthcare Corp. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2013-05-21 |
Phase breakdown
Conditions being studied
| Condition | Trials |
|---|---|
| Colorectal cancer | 2 |
| Pancreatic Cancer | 2 |
| Metastatic Prostate Cancer | 1 |
| Prostate Cancer (Adenocarcinoma) | 1 |
| Prostate cancer | 1 |
| Rectal Adenocarcinoma | 1 |
| Rectal Cancer, Adenocarcinoma | 1 |
Recruiting trials involving Metronidazole
- Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
- Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
- Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
Common questions
Is Metronidazole FDA-approved?
Yes, marketed as Metronidazole. Its FDA label carries a boxed warning.
How many recruiting trials involve Metronidazole?
5 recruiting trials across 7 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.